We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Correction: AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.
- Authors
Gu, Chunyan; Wang, Yajun; Zhang, Lulin; Qiao, Li; Sun, Shanliang; Shao, Miaomiao; Tang, Xiaozhu; Ding, Pinggang; Tang, Chao; Cao, Yuhao; Zhou, Yanyan; Guo, Mengjie; Wei, Rongfang; Li, Nianguang; Xiao, Yibei; Duan, Jinao; Yang, Ye
- Abstract
H-J Proteasome activity assay verified that Bufalin inhibited proteasome activity in (H) ANBL6 WT/DR cells, I ARP1 and H929 AHSA1 WT/OE cells and J PSMD2 WT/OE cells. 1 Elevated AHSA1 expression confers poor survival of MM patients and promotes MM cell proliferation.
- Subjects
CELL proliferation; PROTEASOME inhibitors; MULTIPLE myeloma; BORTEZOMIB; CD38 antigen
- Publication
Journal of Experimental & Clinical Cancer Research (17569966), 2023, Vol 42, Issue 1, p1
- ISSN
1756-9966
- Publication type
Correction Notice
- DOI
10.1186/s13046-023-02672-7